OncoGenex Pharmaceuticals Inc., which pinned its hopes on drug candidates that may boost the effectiveness of existing therapies, is considering its "strategic alternatives" now that its clusterin-targeting asset custirsen has failed in a second Phase III prostate cancer clinical trial.
The AFFINITY trial was the Bothell, Washington-based company's last hope of proving custirsen's value in prostate cancer after the Phase III SYNERGY failure in 2014 caused Teva Pharmaceutical Industries...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?